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The complete amino acid sequence of human spleen apoferritin has been determined. It consists of 174 
amino acids, corresponding to Mr 20017. The sequence is very similar to that of horse spleen apoferritin 
(14% difference between the two sequences). Some peptides were isolated and sequenced which could not 
be placed in the sequence but which are homologous with part of the principal sequence. Automatic 
sequence determination of a large peptide resulting from acid cleavage allows us to establish the presence 
of two homologous sequences (in the ratio 80120). 
Human ferritin Amino acid sequence Microheterogeneity 
1. INTRODUCTION (ii) 
The storage of iron in a soluble, non-toxic and 
bio-available form is assured by ferritin in all the 
classes of living organisms (from man to bacteria). 
The reason for this is not difficult to explain. Iron 
is an essential element for a whole series of en- 
zymes and proteins which range in their functions 
from ribonucleotide reductase, essential for DNA 
synthesis, through nitrogenase, hydrogenase and 
cytochromes, involved in electron transfer, to en- 
zymes which activate oxygen and inactivate reduc- 
ed forms of oxygen (hydroxylases, oxygenases and 
superoxide dismutases, catalases, peroxidases, 
respectively) to oxygen-transport proteins (haemo- 
globins and haemerythrins). However, the 
chemistry of iron in aqueous media at physiolo- 
gical pH is dominated by the tendency of Fe2+ to 
oxidise to Fe3+ and of this latter to hydrolyse and 
polymerise forming insoluble derivatives [ 11. 
Hence, the development of a storage protein which 
enables the stable (and relatively inert) hydrolysed 
Fe III oxyhydroxide to be deposited in the interior 
of a protein shell (apoferritin). 
(iii) 
They provide an essential element for com- 
parative studies on ferritins from different 
species (and notably for the present with the 
ferritin of horse spleen); 
The determination of their amino acid se- 
quence should permit the resolution of a long- 
standing controversy concerning the hetero- 
geneity of ferritins from different tissues of 
the same species [2,3]. 
We present here the complete amino acid se- 
quence of human spleen apoferritins, and its com- 
parison with the primary structure of the horse 
spleen protein. We also draw attention to the 
presence of a minor sequence which may explain 
the apparent heterogeneity of human tissue 
ferritins. 
2. MATERIALS AND METHODS 
The interest of structural studies on human fer- 
ritins are essentially 3-fold: 
(i) They establish the basis for the determination 
of the three-dimensional structure of human 
ferritins; 
Ferritin was isolated from human spleen by a 
procedure involving thermal denaturation, am- 
monium sulphate precipitation and ultracen- 
trifugation at 100000 x g for 2 h. The homogeneity 
of the preparation was controlled by polyacryl- 
amide gel electrophoresis in denaturing (SDS) and 
non-denaturing media, and by amino acid analysis 
after hydrolysis for 16 h in vacua with 6N HCl at 
lOO”C, using a Locarte amino acid analyser 
(Locarte Co., London). 
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Apoferritin was prepared by dialysis against 
thioglycollic acid 1% (v/v) pH 5.5 (Merck, Darm- 
stadt. Prior to cleavage with trypsin and staphylo- 
coccal protease, apoferritin was reduced and car- 
boxymethylated [4] and the lysine residues citra- 
conylated [5] in 7 M guanidine hydrochloride. Car- 
boxymethylated apoferritin was also cleaved with 
trypsin after blocking the arginine residues with 
cyclohexanedione [6]. 
These digests were fractionated by gel filtration 
on Sephadex G-50 in 0.5% (w/v) NbHCOs and 
the smaller peptides were further purified by ion- 
exchange chromatography and by preparative 
paper chromatography. Large staphylococcal pro- 
tease peptides of the N-terminal part of the se- 
quence were digested with pepsin. 
The presence of an Asp-Pro sequence as in the 
horse-spleen ferritin sequence [7] led us to cleave 
the carboxymethylated protein in 70% formic acid 
(v/v) for 4 days at 37°C [8]. We isolated the two 
fragments Pr and PZ by gel filtration on Sepharose 
6B in guanidine hydrochloride (7M). 
The purity of the peptides was established by N- 
terminal analysis using the dansyl chloride pro- 
cedure [9] and by amino acid analysis. Large pep- 
tides were sequenced by liquid-phase Edman 
degradation in a Beckman ‘890B updated’ Se- 
quencer using the programme in [lo]. After con- 
version of the thiazolinones to PTH amino acids, 
identification of the latter was carried out by high- 
pressure liquid chromatography [lo], by gas liquid 
chromatography [1 l] and by thin layer chromato- 
graphy WI. 
The smaller peptides were sequenced by the 
dansyl-Edman method [ 131 and the dansyl amino 
acids were identified by thin-layer chromato- 
graphy. 
3. RESULTS 
We have determined the primary structure of 
human spleen apoferritin on the basis of peptides 
obtained from cleavage with trypsin, staphylococ- 
cal protease, pepsin and from an acid cleavage. We 
present here the sequence which we have establish- 
ed (fig. 1). The homology which exists between the 
sequence of human spleen apoferritin and of horse 
spleen apoferritin [7] helped us to place peptides in 
the sequence for which no overlapping peptides 
were found. 
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The arginyl peptide Tr is ninhydrin negative, 
arginine positive. This peptide was not sequenced 
but its amino acid composition correlates well with 
the N-terminal sequence of horse spleen apofer- 
ritin [7]. 
The large tryptic peptides T2a and Tzb were 
isolated and sequenced togehter in liquid phase 
(Tzb presumably results from residual chymotryp- 
tic activity). S2 covers the sequence of Tza from 
Ala 14 and allows the continuation of the sequence 
up to Ala 43; however, residues 39 and 40 were not 
identified with certainty. 
Peptic peptides SPr-SP3 confirm the region of 
the sequence between residues 24 and 36, and 
sP4-%6 allow us to determine the sequence from 
Val 42 up to Glu 53. Like the tryptic peptides 
T3-T7, they were placed by analogy with the horse- 
spleen ferritin sequence. Some staphylococcal pep- 
tides confirm this part of the sequence. The pep- 
tide TAr obtained by cleavage with trypsin after 
blocking the arginine residues with cyclohexane- 
dione confirms the overlap of T4 and T5 (establish- 
ed by deduction at the time of the determination of 
the horse spleen ferritin sequence). 
The sequence of T7, determined by liquid phase 
degradation, to residue 116 is confirmed by the 
staphylococcal peptides ST-Sir,. The continuation 
of the sequence is assured by Sir up to residue 130. 
The C-terminal sequence is established from Pro 
123 by the peptide PZ up to Ala 159. This sequence 
itself is confirmed by the staphylococcal peptides 
Srr-Si2 and by lysyl peptides (not shown); 
however, we cannot establish the order of the 
residues Lys and Arg in positions 152-153. 
From Leu 154, the tryptic peptide T9 continues 
the sequence which is confirmed by staphylococcal 
peptides Sr4-Srs. As in the horse spleen ferritin se- 
quence, the tryptic peptide Tlo is the C-terminal 
peptide. 
4. DISCUSSION 
The amino acid composition calculated from the 
sequence (table 1) is in good agreement with that in 
[2] and with the values determined on the prepara- 
tions used in the sequence determination (we have 
assumed that the amino acids in positions 39, 40, 
152 and 153 are Asx, Tyr, Arg and Lys, respective- 
ly). The rather low values for Tyr may reflect 
destruction of this amino acid on acid hydrolysis in 
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T2b 
Tl T2a 
NAc-SER-SER-GLN-ILE-AR~-GLN-ASN-TYR-SER-T~~-ASP-VAL-GLU-ALA-A~~-VAL-ASN-TYR-LEU-V~~- 
T2b 
T2a SP3 
SPl I I SP2 _, 
ASN-LE"-TYR-LEU-T;~-ALA-SER-TYR-THR-T~~-LEU-SER-L~U-GLY-P~~-TYR-PHE-ASP-~S~~~~~~ 
s2 54 
T3 
SP4 SP5 SP6 * 
ASP-VAL-ALA-LEU-G;;-GLY-VAL-SER-HIS-P~~-PHE-ARG-GLU-LEU-A~~-GLU-GL"-LYS-ARG-G~~- 
55 
TAl 
T4 T5 
T6 .I T7 
GLY-TYR-GLU-ARG-L~;-LEU-LYS-MET-GLN-A~~-GLN-ARG-GLY-GLY-AR~-ALA-L~"-PHE-GLN-A~~- 
SlO Sll 
T7 
105 II0 1 I5 120 
ALA-LEU-GLU-LYS-LYS-LEU-ASN-GLN-ALA-LEU-LEU-ASP-LEU-HIS-ALA-L~U-GLY-SER-ALA-ARG- 
Sll 512 
121 130 115 
THR-ASP-PRO-HIS-LEU-CYS-ASP-PHE-LEU-GLU-THR-HIS-PHE-LEU-ASP-GLU-GLU-VAL-LYS-~~~- 
P2 
514 
115 I50 155 
ILE-LYS-LYS-MET-GLY-ASP-HIS-LEU-THR-ASN-LEU-(ARG~Y~LEU-GLY-GLY-PRO-GLU-ALA-~~~- 
514 ,, s15 
T9 TlO 
165 170 
LEU-GLY-GLU-TYR-LEU-PHE-GLU-ARG-LEU-THR-LEU-LYS-HIS-ASP 
Fig. 1. Amino acid sequence of human spleen apoferritin. The figure includes the localisation and sequences of tryptic 
(T), staphylococcal protease (S), peptic (SP) peptides, the sequence of one peptide resulting from tryptic cleavage after 
modification of the arginine residues (TA) and the C-terminal peptide resulting from acid cleavage at residues 122- 123 
(P2). 
45 
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(1) NAc-SER-SER-GLN-ILE-AR~-GLN-ASN-TYR-SER-T~~-GLU-"AL-GL"-ALA-A~~-"AL-ASN-ARG-L~"-"~~- 
(2) ASP TYR 
(1) ASN-LEU-TYR-LEU-A~~-ALA-SER-TYR-THR-T~~-LEU-SER-LEU-GLY-P~~-TYR-PHE-ASP-ARG-A~~- 
(2) TYR (ASXWYR) 
(1) ASP-"AL-ALA-LEU-G;;-GLY-"AL-CYS-HIS-P~~-PHE-ARG-GLU-LEU-A~~-GLU-GLU-LYS-ARG-G~~- 
(2) SER 
(3) _ GLY GLU HIS ____ 
(1) GLY-ALA-GL"-ARG-L~;-LEU-LYS-MET-GLN-A~~-GLN-ARG-GLY-GLY-A~~-ALA-LEU-PHE-GLN-A~~- 
(2) - TYR 
(1) LE"-GLN-LYS-PRO-S~~-GLN-ASP-GLU-TRP-G~~-THR-THR-L~"-ASP-A~~-MET-LYS-ALA-ALA-~~~- 
(2) ILE-LYS ~ ALA-GLU LYS - PRO MET- 
(3) SER-GLY-LEU-ASX ~ GLU-CYS - LEU- 
(1) "AL-LEU-GLU-LYS-;~~-LEU-ASN-GLN-ALA-~~~-LEU-ASP-LE"-HIS-~~~-LEU-GLY-SER-ALA-~~~- 
(2) ALA LYS ARG- 
(3) HIS ASX-VAL-ASX-GLX-SER ___ GLU 
125 130 135 lro 
(1) ALA-ASP-PRO-HIS-LEU-CYS-ASP-PHE-LEU-GLU-SER-HIS-PHE-LEU-ASP-GLU-GLU-VAL-LYS-LEU- 
(2) THR THR 
(3) . . . TYR _ ASN ALA 
I't5 150 155 160 
(1) ILE-LYS-LYS-MET-GLY-ASP-HIS-LEU-THR-ASN-ILE-GLN-ARG-LEU-VAL-GLY-SER-GLN-ALA-GLY- 
(2) LEU-(ARG)-(LYS)- GLY - PRO-GLU 
(3) ~ GLU-LEU VAL ARG-LYS-MET - ALA ~ 
165 170 
(1) LEU-GLY-GLU-TYR-LEU-PHE-GLU-ARG-LEU-THR-LEU-LYS-HIS-ASP 
(2) 
Fig. 2. Comparison of ferritin sequences: (1) sequence of horse spleen ferritin; (2) sequence of the principal component 
of human spleen apoferritin; (3) sequence of the minor component of human spleen apoferritin. 
the presence of iron, since the amino acid analyses 
were carried out on ferritin rather than apoferritin. 
The M, of the apoferritin subunit calculated from 
the sequence is 20017, somewhat greater than the 
value of 19824 found for the horse spleen protein 
[7] and some 8% higher than that determined by 
physico-chemical procedures [ 14,151, namely MI 
18500. 
When we compare the amino acid sequence of 
human spleen apoferritin with that of horse spleen 
apoferritin (fig. 2), we see that the homology is 
great, only 25 amino acids of the 174 in the se- 
quence are changed, and most of these changes are 
conservative. Of the substitutions, 18 involve a 
single base change in the corresponding DNA and 
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7 require 2 base changes (those at positions 18, 25, 
39, 62, 85, 105 and 157). The two additional Pro 
residues (93 and 157) in human apoferritin would 
be located, respectively, at the beginning of the C 
helix and in the corner between the D and E helices 
by analogy with the horse spleen apoferritin three- 
dimensional structure [16]. Many of the substitu- 
tions (12 out of the 20) occur in parts of the 
molecule which are located towards the outside of 
the protein shell (that is helices A and C, respec- 
tively residues 1 l-38 and 92-l 18 and the loop L, 
71-91), but until a detailed analysis of the 
substitutions is carried out using the X-ray struc- 
ture of horse spleen apoferritin we cannot be sure 
that the amino acid substitutions are at the external 
Volume 150, number 1 FEBS LETTERS December 1982 
Table 1 
Amino acid composition of human spleen apoferritin 
Amino 
acid 
Number of residues/subunit 
(1) (2) (3) 
CYS 
Asx 
Thr 
Ser 
Glx 
Pro 
GlY 
Ala 
Val 
Met 
Ile 
Leu 
TYr 
Phe 
His 
LYS 
Arg 
Trp 
19 
7 
7 
22 
4 
12 
15 
6 
4 
3 
27 
10 
8 
6 
13 
9 
1.8 1.5 
21.0 20.7 
6.6 7.5 
8.4 8.5 
24.2 24.3 
4.1 4.0 
11.7 11.7 
15.1 15.1 
6.5 6.8 
2.9 3.7 
4.1 3.2 
25.3 23.5 
4.8 6.8 
7.6 7.7 
7.5 7.0 
11.3 11.7 
10.1 8.7 
2.3 n.d. 
n.d., not determined 
The amino acid composition is given as residues of each 
amino acid/M1 20017 subunit; column (1) calculated 
from the amino acid sequence; column (2) from [2]; col- 
umn (3) determined on the preparations used in the 
sequence determination 
surface of the apoferritin molecule. If substitu- 
tions such as those at positions 18 and 25 (Tyr for 
Arg) 82 and 91 (Lys for Glu and Thr, respectively) 
are at the exterior of the protein shell, it is not dif- 
ficult to understand the low degree of im- 
munological cross-reactivity between the two fer- 
ritins. The isoelectric point of horse spleen ferritin 
is 4.4 [17] while that of human spleen ferritin is 
more basic, situated between 5.1-5.7 [3]. In view 
of the uncertainty at certain positions of the se- 
quence (39,40 and 152,153) it is too early to at- 
tempt to explain here the difference in p1 which 
should become clearer from an analysis of the 
three-dimensional structure of horse spleen apofer- 
ritin. We may also note that the sequence 53-60 
which has been implicated [ 181 as being part of the 
catalytic (iron oxidation) site is conserved in both 
ferritins. 
In the course of the sequence determination we 
isolated and sequenced 11 small peptides (in yields 
of 2-9%) which we were not able to place in the 
sequence. The spleen apoferritin preparations con- 
tained lo-20% of the H subunit, which is M, 
1500-2000 greater than the major component, the 
L subunit (these analyses were kindly performed 
by Dr M. Worwood). Liquid phase sequencing of 
Pz, the C-terminal peptide derived from acid 
cleavage, confirmed the presence of a homo- 
logous, but different sequence in amounts cor- 
responding to 15-20%. Fig. 2 lincludes the 69 
amino acid residues of this minor sequence, of 
which 22 are different from the principal sequence 
(all but 6 are single base changes). At this stage, we 
can only suggest hat the minor sequence may cor- 
respond to the lo-20% of H subunit present in the 
ferritin preparations analysed. It is however in- 
teresting, in view of the role of acidic isoferritins in 
regulating bone marrow proliferation [ 191, to note 
that the minor sequence that we have characterised 
is considerably more different from the principal 
human spleen apoferritin sequence (32% dif- 
ferences in amino acid sequence) than is the latter 
from the horse spleen apoferritin sequence (14%). 
The data, in the absence of a complete sequence of 
the minor component, do not allow us to conclude 
that it is a more acidic ferritin, but in the sequence 
described here, there are 5 additional negative 
charges compared to the principal sequence. 
Results of sequence analysis of human placenta 
and HeLa cell ferritins confirm the presence of the 
minor sequence reported here (G. Charlier, per- 
sonal communication). Further studies in progress 
both in our laboratory and using cloned DNA 
should establish the origin of the heterogeneity of 
tissue ferritins. 
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